Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical
  • Published:

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

British Journal of Cancer volume 86, pages 19–25 (2002)Cite this article

Abstract

We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory ovarium cancer. One hundred and seven patients were entered on the study, 98 patients completed the induction therapy consisting of cisplatin at either 50 or 70 mg m−2 weekly for six administrations plus oral etoposide at a dose of 50 mg daily. Of these 98 patients, 38 had a platinum treatment-free interval of more than 12 months, 32 had an interval between 4 and 12 months, and 28 had progressed during or within 4 months after last platinum therapy. We assessed response rates and time to progression, and also response duration and survival. Analyses were done on the 98 evaluable patients. All 107 patients were considered evaluable for toxicity. Of the 38 patients with a treatment-free interval of more than 12 months, 92% responded, with 63% complete responses. The median progression-free survival in these patients was 14 months, and the median survival was 26 months. Of the 32 patients with an interval of 4–12 months, 91% responded, with 31% complete responses, a median progression-free interval of 8 and a median overall survival of 16 months. Of the 28 patients with platinum-refractory disease, 46% as yet responded, with 29% complete responses, median progression-free interval of 5 and an overall survival of 13 months. Haematologic and non-haematologic, particularly renal toxicity and neurotoxicity, were notably mild. We conclude that this intensive regimen of weekly cisplatin plus daily etoposide is highly effective and well tolerated in patients with ovarian cancer relapsing after conventional platinum-based combination chemotherapy, including patients who have progressed during or within 4 months after platinum treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  • Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH (1998) Advanced epithelial ovarian cancer: 1998 consensus statement. Ann Oncol 10: S87–S92

    Article  Google Scholar 

  • Bolis G, Scarfone G, Luchini L, Ferraris C, Zanaboni F, Presti M, Giardina G, Villa A, Parazzini F (1994) Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated and with a cisplatin or carboplatin-based regimen. Eur J Cancer 30A: 1764–1768

    Article  CAS  Google Scholar 

  • Chambers SK, Chambers JT, Kohorn EI, Schwartz PE (1987) Etoposide plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. Gynecol Oncol 27: 233–240

    Article  CAS  Google Scholar 

  • de Wit R, van der Burg MEL, van der Gaast A, Logmans A, Stoter G, Verweij J (1994) Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum containing chemotherapy. Ann Oncol 5: 656–657

    Article  CAS  Google Scholar 

  • Eisenhauer EA, ten Bokkel Huinink W, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N (1994) European-Canadian randomised trial of Taxol in relapsed ovarian cancer: High vs low and long vs short infusion. J Clin Oncol 12: 2654–2666

    Article  CAS  Google Scholar 

  • Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M, Wharton JT (1989) Re-treatment of patients with recurrent epithelial ovarian cancer wit cisplatin-based chemotherapy. Obstet Gyencol 73: 298–801

    Google Scholar 

  • Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore M, Lacave AJ, Mutch D (2000) Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proc ASCO 19: (abstract 1504)

  • Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Rec 2: 837–842

    CAS  Google Scholar 

  • Kavanagh JJ, Nicaise C (1989) Carboplatin in refractary epithelial ovarian cancer. Semin Oncol 16: Suppl 5 45–48

    CAS  PubMed  Google Scholar 

  • Kjorstad K, Harris A, Bertelsen K, Slevin M, Schultz H, Hellman K, Janssens N, Martin A, Canetta R (1992) A multicenter phase II study of carboplatin in advanced ovarian carcinoma. Ann Oncol 3: 217–222

    Article  CAS  Google Scholar 

  • Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davies P, Ognibene FP (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Nat Cancer Inst 86: 18–24

    Article  CAS  Google Scholar 

  • Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of Gemcitabine (2′,2-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Nat Canc Inst 86: 1530–1533

    Article  CAS  Google Scholar 

  • Mabel JS (1979) Therapeutic synergism in murine tumours for combination of cis-diamminedichloroplatinum with VP 16--213 or BCNU. Proc Am Assoc Cancer Res 20: 230

    Google Scholar 

  • Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis Jr JL (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with Cisplatin. J Clin Oncol 9: 389–393

    Article  CAS  Google Scholar 

  • Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicine in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987–993

    Article  CAS  Google Scholar 

  • Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E, van Lent M (1991) Long-term survival in ovarian cancer. Eur J Cancer 27: 1367–1372

    Article  CAS  Google Scholar 

  • Ozols RF, Ostshega Y, Curt G, Young RC (1987) High-dose carboplatin in refractory ovarian cancer. J Clin Oncol 5: 197–201

    Article  CAS  Google Scholar 

  • Planting AS, van der Burg ME, de Boer-Dennert M, Stoter G, Verweij J (1993) Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer 68: 789–792

    Article  CAS  Google Scholar 

  • Planting AST, van der Burg MEL, Goey SH, Schellens JH, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1995) Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumours. Ann Oncol 6: 190–192

    Article  CAS  Google Scholar 

  • Rose PG, Blessing JA, Mayer AR, Homesley HD (1998) Prolonged oral etoposide as second-line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology group Study. J Clin Oncol 16: 405–410

    Article  CAS  Google Scholar 

  • Seltzer V, Vogl S, Kaplan B (1985) Recurrent ovarian carcinoma: retreatment using combination chemotherapy including cis-diaminechloroplatinum in patients previous responding to this agent. Gynecol Oncol 21: 167–176

    Article  CAS  Google Scholar 

  • ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2182–2193

    Article  Google Scholar 

  • Tropé C, Hogberg T, Kaern J, Bertelsen K, Bjorkholm E, Boman K, Himmelmann A, Horvath G, Jacobsen A, Kuopolla T, Vartianen J, Lund B, Onsrud M, Puistola U, Salmi T, Scheistroen M, Sandvei R, Simonsen E, Sorbe B, Tholander B, Westberg R (1998) Long-term results from phase II study single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience. Ann Oncol 9: 1301–1307

    Article  Google Scholar 

  • van der Burg ME, de Wit R, Stoter G, Verweij J (1998) Phase I study of weekly cisplatin (P) and weekly or 4-weekly taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC). Proc ASCO 17: (abstract 1370)

  • van der Burg ME, Hoff AM, van Lent M, Rodenburg CJ, van Putten WL, Stoter G (1991) Carboplatin and Cyclophosphamide salvage therapy for ovarian cancer patients relapsing after Cisplatin combination chemotherapy. Eur J Cancer 27: 248–250

    Article  CAS  Google Scholar 

  • WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment WHO Offset Publications No. 48Geneva: World Health Organization

Download references

Acknowledgements

The Dutch Cancer Society for support of the study CKVO 94--09. The medical oncologists and gynecologists of the Comprehensive Cancer Center Rotterdam. R Dercksen, Trial Office.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Rotterdam Cancer Institute and University Hospital, Rotterdam, P.O. Box 5201, Rotterdam, 3008, AE, The Netherlands

    M E L van der Burg, R de Wit, W H J Kruit, G Stoter & J Verweij

  2. Department of Gynecology, Rotterdam Cancer Institute and University Hospital, Rotterdam, 3008, AE, The Netherlands

    A Logmans

  3. Biostatistics, Rotterdam Cancer Institute and University Hospital, Rotterdam, 3008, AE, The Netherlands

    W L J van Putten

Authors
  1. M E L van der Burg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R de Wit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W L J van Putten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Logmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W H J Kruit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Stoter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R de Wit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Burg, M., de Wit, R., van Putten, W. et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86, 19–25 (2002). https://doi.org/10.1038/sj.bjc.6600002

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bjc.6600002

Keywords

This article is cited by

Search

Advanced search

Quick links